EGFR and esophageal squamous cell carcinoma: To detect the interaction between the EGFR/HER2 inhibitor and the IGF-1R inhibitor, lapatinib or gefitinib was mixed with linsitinib at a fixed ratio (1:4) to treat the ESCC cells for 48 h.